


Regulatory Announcement

[Go to market news section](#)

 Free annual report  

Company	Cobra Bio-Manufacturing PLC
TIDM	CBF
Headline	Advaxis Contract
Released	07:00 22-Oct-07
Number	0628G



For Immediate Release

22 October 2007

Cobra Biomanufacturing Plc

Cobra Signs Agreement with Advaxis to Manufacture Lovaxin C Vaccine

Keele, UK, 22 October 2007 - UK based Cobra Biomanufacturing Plc (AIM: CBF) has signed an agreement with North Brunswick, NJ based Advaxis (OTCBB: ADXS) to manufacture Phase II clinical trial material of a therapeutic cervical cancer vaccine known as *Lovaxin C*.

Commenting on the contract: David Thatcher, CEO at Cobra, said: "We have been supporting the Advaxis *Lovaxin C* clinical program since 2003 and are delighted to extend our work with Advaxis on this exciting project."

Commenting on the contract: John Rothman, Vice President, Clinical Development, said: "We look forward to continuing our relationship with Cobra as we move forward with the development of live *Listeria* vaccines for the treatment of cancer. Our initial clinical work demonstrated the real world utility of our concepts, and Cobra's ability to execute their production as potential cancer immunotherapeutic agents."

Notes for Editors:

About: *Lovaxin C* Vaccine

Based on over a decade of work in the laboratory of Dr. Yvonne Paterson at the University of Pennsylvania, the Company's broadly enabling *Listeria* technology platform uses modified *Listeria monocytogenes* to deliver a tumor-specific antigen fusion protein. *Listeria* has the ability to generate a robust immune response and produce an unusually strong and effective therapeutic immune response to existing cancers and other diseases affecting many related immune mechanisms simultaneously and in an integrated fashion. 'Advaxis' *Listeria*-based technology not only generates an unusually profound cytotoxic immune response capable of killing cancer cells, but the Company's proprietary antigen fusion protein technology minimizes the suppressive effects of regulatory T cells that appear to inhibit many vaccines, and also creates a local tumor environment conducive to the therapeutic effects of the activated tumor killing cells.

Unlike current products on the market, which are ineffective in women already infected with HPV, which causes

cervical cancer, Lovaxin C is designed to treat women who have already developed cervical cancer as a result of the HPV infection.

About Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpins a successful revenue generating contract manufacturing business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. Since floatation the Company has grown turnover from £3 million to £10 million providing expert manufacturing services across the world with over 80% of revenues currently from the US market.

www.cobrabio.com

Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research, which is, by nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue.

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes multiple simultaneous immunological mechanisms to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

- ENDS -

For further information, please contact:

Cobra Biomanufacturing Plc

David Thatcher, Chief Executive Officer

Tel: +44 (0) 1782 714 181

Buchanan Communications

Tim Anderson/Mark Court/Rebecca Skye Dietrich

Tel: +44 (0) 207 466 5000

Northbank Communications

Gemma Price

Tel: +44 (0) 207 268 3240

Advaxis Inc

Thomas A Moore (moore@advaxis.com)

Tel: +1 732 545 1590

Investor Relations/Public Relations Contact:

Investors Relations Group:

Antima (Taz) Sadhukhan

Tel: +1 212 825 3210

Media Contact:

Janet Vasquez, Public Relations

Tel: +1 212 825 3210

END

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2007 London Stock Exchange plc. All rights reserved